Joining the ranks of hydroxychloroquine, Remdesivir showed no reduction in outcomes or ventilator rates in people infected with COVID-19. Which is too bad, it would be nice to have more effective drugs against this virus. But anti-viral medication is tricky stuff, and we've only been fighting this particular bastard for ten months.
https://www.reuters.com/article/health-coronavirus-remdesivir/who-study-says-remdesivir-did-not-reduce-mortality-in-covid-19-patients-ft-idINL4N2H63XG
https://www.reuters.com/article/health-coronavirus-remdesivir/who-study-says-remdesivir-did-not-reduce-mortality-in-covid-19-patients-ft-idINL4N2H63XG
no subject
Date: 2020-10-18 04:42 pm (UTC)What I would like to see is something like a cap on what you can charge, plus a repayment where a percentage of your profits goes back into the NIH research grant fund.